Company analysis
What these companies build, how far along they are, and who backs them
What they build
By sector
By modality (top 12)
By indication (top 12)
By region
Sector × region
Companies per sector and region. Shading is relative to the largest cell on a square-root scale, so small counts stay visible.
| United States | Europe | Greater China | Israel | South Korea | Canada | Japan | Rest of World | India | Southeast Asia | Australia & New Zealand | Taiwan | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Therapeutics / BioPharma | 54 | 134 | 24 | 20 | 28 | 18 | 17 | 13 | 29 | 6 | 12 | 16 |
| MedTech / Medical devices | 55 | 25 | 10 | 10 | 7 | 12 | 9 | · | 3 | 4 | 10 | 2 |
| Digital health | 39 | 18 | 16 | 6 | 3 | 5 | 7 | 6 | 5 | 9 | 5 | · |
| Diagnostics / Precision testing | 39 | 24 | 7 | 4 | 6 | 3 | 5 | 4 | 1 | 5 | 4 | 4 |
| Healthcare services / Care delivery | 25 | 6 | 11 | · | 1 | 2 | 1 | 29 | 2 | 15 | 3 | · |
| Healthcare IT / Infrastructure | 47 | 13 | 1 | 3 | 2 | 11 | 2 | 1 | 1 | 2 | 3 | · |
| Cell & gene therapy | 30 | 12 | 4 | 4 | 1 | 1 | 7 | · | 2 | 4 | · | 2 |
| Medical imaging | 18 | 9 | 5 | 5 | 7 | 1 | 5 | · | 4 | 1 | 7 | 2 |
| Pharma services (CRO/CDMO) | 4 | 10 | 6 | · | 2 | · | 3 | 2 | 7 | 1 | · | 5 |
| AI drug discovery / TechBio | 12 | 8 | 2 | 7 | 2 | 2 | 3 | 1 | · | 1 | · | · |
| Consumer health / Wellness | 14 | 7 | 2 | 1 | · | · | 2 | 3 | 1 | 1 | 2 | · |
| Life-science tools / Instruments | 6 | 9 | · | 1 | 2 | 5 | 1 | · | 1 | 2 | · | · |
How far along
Clinical pipeline
Where each company's lead program sits today. A snapshot, not an attrition curve — nobody dropped out between these rungs, and only companies with a clinical stage on record appear at all.
By corporate status
Regulatory clearances, by body
Companies holding at least one clearance, approval or designation from each body. Counted once per company, however many filings it has.
How they exited
Exit type is free text in the source records; these are folded buckets.
When they were founded
Founding year
689 of 1,279 companies have a founding year on record. The drop after 2019 is a sourcing artefact — young private companies are the hardest to document — not a real collapse in company formation.
Who backs them
Link coverage
Both-sides corroboration and the backlog come from the build's link table; every other number on this page is counted live from the company records.
Most-backed companies
- 1Cityblock HealthUnited States · Healthcare services / Care delivery12investors
- 2Devoted HealthUnited States · Healthcare services / Care delivery12investors
- 3TranscarentUnited States · Healthcare services / Care delivery12investors
- 4AdvanCellAustralia & New Zealand · Therapeutics / BioPharma11investors
- 5Ambience HealthcareUnited States · Digital health11investors
- 6HalodocSoutheast Asia · Digital health11investors
- 7Maven ClinicUnited States · Healthcare services / Care delivery11investors
- 8SomatusUnited States · Healthcare services / Care delivery11investors
- 9Thyme CareUnited States · Healthcare services / Care delivery11investors
- 10DispatchHealthUnited States · Healthcare services / Care delivery10investors
- 11FreenomeUnited States · Diagnostics / Precision testing10investors
- 12Hinge HealthUnited States · Healthcare services / Care delivery10investors
Most active investors here
- 1ARCH Venture PartnersUnited States · Life-science VC firm20companies
- 2GVUnited States · Corporate VC (pharma / medtech / payer / provider / tech)20companies
- 3SV Health InvestorsEurope · Growth equity / late-stage13companies
- 4SoftBank Vision FundJapan · Growth equity / late-stage13companies
- 5a16z Bio + HealthUnited States · Life-science VC firm13companies
- 6General Catalyst (Health Assurance)United States · Life-science VC firm12companies
- 7Oxford Science EnterprisesEurope · Venture studio / company creation (Flagship model)11companies
- 8Fidelity Management & Research CompanyUnited States · Crossover fund (private + public biotech)11companies
- 9KinnevikEurope · Crossover fund (private + public biotech)10companies
- 10ClavystBioSoutheast Asia · Government / public program / sovereign fund10companies
- 11Eli Lilly and CompanyUnited States · Corporate VC (pharma / medtech / payer / provider / tech)10companies
- 12Sequoia CapitalUnited States · Life-science VC firm10companies
Unicorns
- 1League Inc.Canada · Digital health
- 2AlanEurope · Digital health€5 billion
- 3CeraEurope · Healthcare services / Care delivery
- 4CMR SurgicalEurope · Surgical robotics$3bn
- 5DoctolibEurope · Digital health€5.8 billion
- 6Neko HealthEurope · Diagnostics / Precision testing$1.8 billion
- 7OuraEurope · Consumer health / Wellness$11 billion
- 8Sword HealthEurope · Digital health$3 billion (2024)
- 9iCarbonXGreater China · Genomics / Multi-omics
- 10Molbio DiagnosticsIndia · Diagnostics / Precision testing$1 billion+
- 11OrCam TechnologiesIsrael · Consumer health / Wellness$1.5B
- 12BetterflyRest of World · Consumer health / Wellness$1 billion
- 13MiRXESSoutheast Asia · Diagnostics / Precision testing
- 14AbridgeUnited States · Digital health$5.3B
- 15Assort HealthUnited States · Digital health$1.2B
- 16Butterfly NetworkUnited States · Medical imaging$1.25 billion
- 17Cityblock HealthUnited States · Healthcare services / Care delivery$5.7 billion
- 18CommureUnited States · Healthcare IT / Infrastructure$7B
- 19Enveda BiosciencesUnited States · AI drug discovery / TechBio
- 20Grow TherapyUnited States · Healthcare services / Care delivery
- 21Hippocratic AIUnited States · Digital health$3.5B
- 22InnovaccerUnited States · Healthcare IT / Infrastructure$3.45 billion
- 23Iodine SoftwareUnited States · Healthcare IT / Infrastructure>$1B
- 24Maven ClinicUnited States · Healthcare services / Care delivery$1.35 billion
- 25Omada HealthUnited States · Healthcare services / Care deliveryjust above $1 billion
- 26OpenEvidenceUnited States · Digital health$12B
- 27SomatusUnited States · Healthcare services / Care deliveryover $2.5 billion
- 28TranscarentUnited States · Healthcare services / Care delivery$2.2 billion
What this page can't tell you
Only 55 of 1,279 companies (4%) have a disclosed total raised, and 39 a valuation — which is why this page carries no funding-size chart. A distribution drawn from that slice would describe how easy the money was to source, not how the market works. 689 have a founding year. Every record is rated for source confidence: